Additionally, patients with EGFR-mutated lung cancer, positive for RET fusions at the time of progression on osimertinib, who received the combination of the third-generation TKI and the RET inhibitor selpercatinib, gained clinical benefit associated with a safety profile [251]. This evidence concerns the gene EGFR and lung carcinoma.